Brands of Tobramycin Ophthalmic in Kenya
Bracin Eye Drops, ATCO Laboratories Limited
Tobrex Eye Drops, Novartis Pharma AG
MODE OF ACTION
Appears to inhibit protein synthesis in susceptible bacteria by irreversibly binding to 30S and 50S ribosomal subunits
INDICATIONS
Tobramycin ophthalmic is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic.
Clinical studies have shown tobramycin to be safe and effective for use in children.
DOSAGE AND ADMINISTRATION
In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.
CONTRAINDICATIONS
Tobramycin ophthalmic solution, is contraindicated in patients with known hypersensitivity to any of its components.
DRUG INTERACTIONS
No clinically relevant interactions have been described with topical ocular dosing.
WARNINGS
FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION INTO THE EYE. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution occurs, discontinue use.
ADVERSE EFFECTS
The most frequent adverse reactions to Tobramycin Ophthalmic Solution USP are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with Tobramycin Ophthalmic Solution USP.
Postmarketing Experience:
Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Tobramycin Ophthalmic in Kenya
Tobramycin Ophthalmic in Kenya
Tobramycin Ophthalmic in Kenya
Tobramycin Ophthalmic in Kenya
Tobramycin eye drops in Kenya
Tobramycin eye drops in Kenya
Tobramycin eye drops in Kenya
Tobramycin eye drops in Kenya
Tobramycin eye drops in Kenya
Tobramycin eye drops in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: N (Not classified yet)
Routes of Administration: ophthalmic
Bioavailability: Not Available
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action: N/A
Elimination Half life: Not Available
Excretion: Not Available
Legal Status | Dosage forms & Strengths
Prescription Category:
Prescription only Medicine (POM) , â„ž-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Drug Indentifiers:
| CAS Number | |
|---|---|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | |
Drug Images
References/ Citation:
- PPB Drugs Retention Register
- Cochereau, Isabelle, et al. “3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.” British journal of ophthalmology 91.4 (2007): 465-469.
- Kernt, K., et al. “A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.” European journal of ophthalmology 15.5 (2005): 541-549.